New drug duo aims to tame tough prostate cancer
NCT ID NCT06130995
Summary
This early-stage trial is testing if combining two medications, relugolix and enzalutamide, can better control high-risk, locally advanced prostate cancer. About 46 men will take these drugs before and after their standard treatment, which is either surgery or radiation therapy. The main goals are to find a safe dose and see if this combination helps eliminate more cancer cells and prevents the disease from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC)
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.